Phase I study of CH5132799 in patients with advanced solid tumors

• Research type

  Research Study

• Full title

  Phase I, open-label, multi-center, dose-escalation study with extension to evaluate safety, pharmacokinetics and activity of CH5132799, a PI3K inhibitor administered orally as a monotherapy in patients with advanced solid tumors

• IRAS ID

  38981

• Contact name

  Udai Banerji

• Contact email

  udai.banerji@icr.ac.uk

• Eudract number

  2009-017196-14

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  exceeds word count do not publish

• REC name

  London - Chelsea Research Ethics Committee

• REC reference

  10/H0801/14

• Date of REC Opinion

  12 Apr 2010

• REC opinion

  Further Information Favourable Opinion